Detalles de la búsqueda
1.
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
Lancet Oncol;
25(1): 29-45, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101433
2.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol;
25(1): 46-61, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101431
3.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol;
25(1): 99-107, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38043558
4.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol;
25(5): 563-571, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621400
5.
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer.
BJU Int;
2024 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38469652
6.
The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
BJU Int;
133 Suppl 3: 39-47, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37604702
7.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int;
133 Suppl 3: 57-67, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986556
8.
A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity.
World J Urol;
42(1): 115, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38436768
9.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol;
24(4): 323-334, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36990608
10.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol;
23(11): 1389-1397, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36261050
11.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet;
397(10276): 797-804, 2021 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581798
12.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med;
381(2): 121-131, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31157964
13.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med;
20(1): 112, 2022 03 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331214
14.
'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
BJU Int;
129(5): 591-600, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34273231
15.
Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry.
Psychooncology;
31(3): 496-503, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34623735
16.
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Intern Med J;
52(8): 1339-1346, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33710759
17.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet;
395(10236): 1547-1557, 2020 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416780
18.
A phase I open label dose-escalation study to evaluate the tolerability, safety and immunological efficacy of sub-urothelial durvalumab injection in adults with muscle-invasive or high-risk non-muscle-invasive bladder cancer (SUBDUE-1, SUB-urothelial DUrvalumab injection-1 study): clinical trial protocol.
BJU Int;
128 Suppl 1: 9-17, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33960102
19.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int;
128(5): 642-651, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34028967
20.
UpFrontPSMA: a randomized phase 2 study of sequential 177 Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol).
BJU Int;
128(3): 331-342, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33682320